NCT06914661Enrolling by invitation
Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment
Multicenter Real-world Study on the Efficacy and Safety of DS8201 in the Treatment of Metastatic Breast Cancer
Source: ClinicalTrials.gov · Last updated 8 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study analyzes the use of DS8201 in the treatment of metastatic breast cancer in the real world by analysis, exploring whether there are differences in effectiveness and safety between real-world conditions and clinical trials.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 31 Mar 2025
- Start date
- 25 May 2025
- Primary completion date
- 30 Aug 2025
- Lead sponsor
- The First Hospital of Jilin University
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06914661
What you commit to
- Study type: Observational
- Planned participants: 200
- From 25 May 2025 to the primary completion date, 30 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Hospital of Jilin University Coordinator of this site? Confirm its status | Changchun | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.